Richie J P
Harvard Program in Urology (Longwood Area), Harvard Medical School, Boston, Massachusetts.
Urol Clin North Am. 1992 Aug;19(3):521-7.
A variety of chemotherapeutic agents are available for the patient with rapidly recurring superficial bladder cancer. Management should have two therapeutic goals--ablation of existing tumors and prevention of tumor recurrence. Stage, grade, and multicentricity are all important factors in the decision for therapeutic intervention. Intravesical instillation of chemotherapeutic agents can reduce the rate of recurrence of superficial tumors but has not yet been proved to lower the incidence of later muscle-invasive tumors. Different dosage schedules and methods require further study. Empiric dose schedules may not provide optimal therapeutic effects. The question of timing of instillation of agents after definitive resection needs clarification as well. Questions that remain can be answered only through appropriately designed studies encompassing large numbers of patients with treatments assigned in a randomized fashion.
对于快速复发的浅表性膀胱癌患者,有多种化疗药物可供使用。治疗应具有两个治疗目标——消除现有肿瘤并预防肿瘤复发。分期、分级和多中心性都是决定治疗干预的重要因素。膀胱内灌注化疗药物可降低浅表肿瘤的复发率,但尚未被证明能降低后期肌层浸润性肿瘤的发生率。不同的给药方案和方法需要进一步研究。经验性给药方案可能无法提供最佳治疗效果。在根治性切除后药物灌注的时机问题也需要明确。剩下的问题只有通过精心设计的研究才能回答,这些研究要纳入大量患者,并以随机方式分配治疗方案。